Telsey Advisory Group analyst Joseph Feldman maintains Five Below (NASDAQ:FIVE) with a Outperform and raises the price target from $150 to $175.
Cantor Fitzgerald Maintains Overweight on Insmed, Lowers Price Target to $46
Cantor Fitzgerald analyst Jennifer Kim maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $49 to $46.